33 results about "Osmotic concentration" patented technology

The invention discloses a bicarbonate physiological balanced solution which belongs to the field of infusion preparations and is prepared form the following raw materials: sodium chloride, potassium chloride, calcium chloride, magnesium sulfate, sodium bicarbonate, glucose, citric acid and trisodium citrate. All the raw materials are accurately weighed according to corresponding portions, and dissolved in water for injection; the volume is determined; medical standard CO2 gas is introduced; the pH value is adjusted; and the solution is filtered, filled, packed, sterilized, labeled and then stored at room temperature. The solution has the advantages that ion components and a penetration concentration are similar to those of extracellular fluid and have physiological performance. The balanced solution is suitable for supplementing the extracellular fluid by injection, intravenous drip or oral administration, has an adjustment function for acid-base balance, and is also used as a surgical washing fluid or buffering solution.

A pressurized forward osmotic separation process is disclosed. Generally there are two processes described. One process involves the concentration of a target solute in the first solution; the other process involves the extraction of a solvent from a first solution both by a second solution comprising of water and soluble gas or water, soluble gas, and a compound by creating an osmotic concentration gradient across the semi permeable membrane. The first solution is under pressure from an inert gas and the second solution is under pressure from a soluble gas with equal system pressures greater than 1 atmosphere. The increase or decrease of partial pressure of the soluble gas in the second solution increases or decreases the chemical potential of the second solution to achieve different solution properties. The soluble gas may be carbon dioxide and the compound may be magnesium hydroxide.

The invention relates to an Rh group incompatibility therapeutic apparatus in the field of medical science. The Rh group incompatibility therapeutic apparatus is characterized in that rhesus monkey red blood cells containing human common Rh antigen are alternately washed by PB lysate with the osmotic concentration of 25 and 35mmol/L, ghost cells dialyzed with hemoglobin, retaining Rh antigenicity and capable of adsorbing an Rh antibody are prepared and fixed to agarose with special concentration together with the Rh antibody prepared by immunology according to a specific ratio, the agarose is placed into a cylindrical adsorber made of high-biocompatibility materials, antibody valence from high to low and agarose concentration from low to high are formed from a sample inlet end to a sample outlet end, the ghost cells are uniformly distributed, red blood cell destruction products of patients suffering from group incompatibility can be effectively intercepted by the agarose with gradually increased special concentration and gradually decreased molecular micropores at the sample inlet end and the sample outlet end and a mesh screen at an outlet of the adsorber, and a novel therapeutic method for maternal fetal Rh group incompatibility does not remove plasma components and avoids toxic and side effects.

Provided are thin film composite membrane structures comprising: a selective membrane layer for ion rejection attached to a support layer, the support layer comprising a multi-zone microfiltration membrane comprising: a porous support material; and at least two microfiltration zones, where a first zone comprises a first membrane and a second zone that is attached to the first zone and that coats at least a portion of the porous support material. Thin film composite membrane structures may be provided in reverse osmosis systems or nanofiltration systems. Also, thin film composite membrane structures may be provided in direct osmotic concentration systems, forward osmosis systems, or pressure retarded osmosis systems.

The present invention provides a synchronic monitor system using real-time ultrasound image to monitor the permeable concentration of the targeted tissue for drug delivery induced by ultrasound. The drug delivery is performed by using a first ultrasound apparatus to emit a first ultrasound to a blood vessel of the targeted tissue to allow a drug passing through the blood vessel into a lesion zone. The synchronic monitor system comprises a second ultrasound apparatus and software. The second ultrasound apparatus has a transducer, and the transducer is used to emit a second ultrasound to the blood vessel to determine several information of the blood flow. The software is installed in the second ultrasound apparatus to collect the information of the blood flow, and calculate an extravasation of the drug in the lesion zone according to the information of the blood flow via a first equation. The present invention discloses a method using the same.

The invention relates to an adsorption herapeutic apparatus for maternal-fetal blood group incompatibility, relating to the medical field. The apparatus is characterized by comprising following steps: utilizing PB of 25 and 35 mmol/L as lysate, fully washing Rh positive O-type erythrocytes and cleaning them with normal saline to make ghost cells with dialysis of ferrohemoglobin and antigen performance capable of effectively absorbing Rh antibodies, utilizing 0.9%, 1.0%, 1.1%, 1.2% and 1.3% of agarose which is melt at 100 DEG C and kept in 56 DEG C to make adsorbents of 95% of ghost cell concentration, orderly taking 55-65ml according to ghost cell concentration from high to low to be added into a cylindrical container made by material with high biocompatibility so that an absorber enabling adsorbents from a sample inlet end to a sample outlet end to form uniform distribution of ghost cells and agarose concentration from low to high, using the above to clear Rh anti-bodies in plasmas filtered by the absorber and macromolecule disease-causing substances generated by destroyed erythrocyte such that the treatment purpose of preventing Rh anti-bodies of pregnant women from entering fetus blood and lightening condition is achieved.

The invention relates to a method and apparatus for treatment of produced or process water from hydrocarbon production to reduce the volume of the produced or process water while simultaneously reducing the salinity of a highly saline stream, for example, the brine from a seawater desalination plant. The method includes causing a feed stream comprising produced or process water to flow through the lumen of a hollow fiber osmotic membrane 4 which is immersed in an open channel 2 or tank of flowing draw solution 6 which has high salinity. In this way, water from the feed stream is drawn through the osmotic membrane 4 by an osmotic pressure differential caused by the difference in salinity between the feed stream and the draw solution 6.

This invention is referred to the field of medicine, namely preventative treatment, and may be used as a means of synergetic minimization of negative impact of flights on human health (brain, stomach, lungs, blood vessels, heart etc.) with application of known substances and medicines with newly discovered pharmacological properties in new conditions. The ultimate technical solution of this invention would be synergetic minimization of negative impact of flying on human health without foot swelling, belching, jet-lag, tiredness and fatigue etc. The claimed technical result is achieved by the method of synergetic minimization of negative impact of air flights on human health, including consumption of substances that improve osmotic concentration of blood plasma, in the form of oral rehydration solution, split into two intakes as a minimum, first intake in the amount of at least 0.3 liters up to 1 liter before boarding and further during the flight from half an hour to 2 hours at least 0.3 liters to 1 liter and on as-needed basis.

The invention relates to a buried type agricultural irrigation system capable of adjusting osmotic concentration. The irrigation system comprises a main pipeline, a secondary pipeline, a drainage portand a regulating valve, wherein the drainage port is formed in the secondary pipeline, the regulating valve is arranged on the joint between the drainage port and the secondary pipeline, a first semi-permeable membrane is arranged on the joint between the main pipeline and the secondary pipeline, a second semi-permeable membrane is arranged on the joint between the secondary pipeline and the drainage port, the regulating valve is connected with a regulating water tank, the regulating water tank regulates the concentration of an aqueous solution in the secondary pipeline, the first semi-permeable membrane is used for taking water from the main pipeline, the second semi-permeable membrane is used for irrigating the outside through the drainage port, the irrigation system further comprises amonitoring system, the monitoring system further comprises a flow instrument, a first flow velocity meter, a second flow velocity meter, a third flow velocity meter and a control meter, the first flow velocity meter, the second flow velocity meter and the third flow velocity meter measure the water velocities on the first semi-permeable membrane, second semi-permeable membrane and regulating valve respectively, the flow instrument detects the amount of water discharged from the drainage port, and the control meter controls the regulating valve to adjust the irrigation speed and irrigation amount of the irrigation system.

The invention provides a plant cold-resisting antifreezing agent. The plant cold-resisting antifreezing agent is prepared from, by weight, 3-9 parts of corn juice, 6-12 parts of ephedra extracting solution, 8-12 parts of rapin, 4-7 parts of silver thiosulfate, 4-6 parts of monopotassium phosphate, 2-4 parts of paclobutrazol, 0.5-1 part of lysine, 0.5-0.8 part of cysteine, 3-6 parts of garlic filter liquor, 0.5-1 part of maltose, 1-2 parts of potato starch, 2-3 parts of algal polysaccharides, and 2-3 parts of polylactic acid. According to the plant cold-resisting antifreezing agent, cysteine is added for resisting and destroying crop germs; lysine has unique photosynthesis and regulating effect to crops; maltose and potato starch added for rapidly improving content of sugar in a plant cell, so that the cell osmotic concentration is improved, the water potential is reduced, and the water retaining capacity is increased; meanwhile, the cell heat is added, freezing in the cell and the cell frozen dehydration are avoided; thus the low-temperature resistance and cold resistance of the plant are improved.

Disclosed is a system for measuring mass transfer in a membrane and solutions. The system includes: a membrane module 10 including a feed solution reservoir 11 accommodating a feed solution f, a draw solution reservoir 13 accommodating a draw solution d whose osmotic concentration is higher than that of the feed solution f, and a holder 15 supporting a semipermeable membrane m arranged between the feed solution reservoir 11 and the draw solution reservoir 13 and whose performance is to be measured; a feed solution storage tank 20 storing the feed solution f; and a feed solution supply pump 30 supplying the feed solution f from the feed solution storage tank 20 to the feed solution reservoir 11 at a fixed flow rate corresponding to a water flux WF across the membrane m such that the water flux WF is maintained constant.

The invention discloses a novel high-salt mercury-containing wastewater concentration method. A forward osmosis concentration technology and an evaporation concentration technology are effectively combined; mercury-containing wastewater is subjected to evaporative crystallization treatment; wherein the forward osmosis concentration technology and the membrane separation technology utilize physicalcharacteristics driven by osmotic pressure; pure physical separation and osmotic concentration processes are adopted, phase change is avoided, the energy consumption is low, the process is simple, dechlorinated light salt brine is used as a draw solution, the draw solution is diluted and then re-injected into a salt well, waste water needing to be treated outside cannot be generated, resources ofthe chlor-alkali industry are fully utilized, zero emission is achieved, the process efficiency is improved, energy consumption is reduced, and the operation cost is reduced.

The invention provides an ambrisentan aerosol inhalation solution as well as a preparation method and application thereof. A single dose of the ambrisentan inhalation solution comprises 0.1-20mg of ambrisentan, a buffering agent, an isoosmotic adjusting agent and a solvent, and can also comprise a pH (Potential of Hydrogen) adjusting agent. The single dose specification of the inhaled solution is 1-5 ml. The dosage of the buffering agent is 0.01%-0.5%; the isoosmotic adjusting agent is added to enable the inhalation solution to have the molecular osmotic concentration by weight of 200-400 mOsmol/kg; the addition amount of the pH regulator enables the pH value of the inhalation solution to be 6.5-10.0. The ambrisentan aerosol inhalation solution is combined with the liquid atomization device, and the ambrisentan aerosol inhalation solution drug dosage form and the drug delivery system which are convenient to use, safe, effective and good in stability can be provided.

The invention provides an inhalation umeclidinium bromide solution, a preparation method and application thereof, the inhalation solution comprises an active substance, a solvent and auxiliary materials, the single dose specification of the inhalation solution is 1-5ml, and the active substance in the single dose specification is 20-100 micrograms of umeclidinium bromide; the solvent is sterile injection water; the auxiliary materials comprise an isoosmotic adjusting agent and a pH adjusting agent; the adding amount of the isoosmotic adjusting agent is such that the inhalation solution has a weight gram molecule osmotic concentration of 240-400mOsmol/kg; the pH regulator is added so that the pH value of the inhalation solution preparation is 4.0-6.0. The device for combining the ullidinium bromide solution for inhalation with an atomized aerosol can provide a medicine dosage form of the ullidinium bromide for inhalation, which is convenient to use, safe, effective and good in stability, and an administration system.